Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Listed
Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,836 across all filing types
Latest filing 2026-05-12 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB · 20 venues

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 93% confidence The document is a Company Announcement detailing the terms and effects of a share capital increase following the exercise of employee warrants, including number of new shares, subscription prices, and updated nominal share capital. This is a direct announcement of a change in the company’s capital structure (new share issuance). It does not present a full financial report, earnings release, or AGM materials, nor is it a mere publication notice. It fits the definition of "Share Issue/Capital Change" (Code: SHA).
2026-05-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 87% confidence The document is a corporate announcement detailing an increase in share capital resulting from the exercise of employee warrants. It is an announcement of new share issuance/capital change (number of new shares, nominal value, pricing, and registration details). There are no financial statements or regulatory certifications—just a notice of share capital adjustment. This fits the “Share Issue/Capital Change” category (SHA).
2026-05-12 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is a notification of major shareholding, detailing the acquisition of voting rights crossing a threshold (5.0783%) in a company (GENMAB A/S). It includes specific data about voting rights, share capital, and the chain of controlled undertakings. This type of document corresponds to a Major Shareholding Notification, which is used to inform regulatory bodies and the market about significant changes in share ownership levels.
2026-05-08 Danish
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major Shareholder Announcement' and references a notification under Section 30 of the Danish Capital Markets Act regarding Orbis Investment Management Limited's voting rights in Genmab A/S. It details the percentage of shares controlled and voting rights, which is typical for a major shareholding notification. The document is short (3916 characters) and focuses solely on the announcement of a change in significant share ownership levels. There is no financial data, report, or other content that would classify it as an annual report, earnings release, or other financial filing. Therefore, the document fits the category of Major Shareholding Notification (MRQ).
2026-05-08 Danish
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major Shareholder Announcement' and explicitly states that Orbis Investment Management Limited has informed the company about controlling 5.08% of the voting rights. It references Section 30 of the Danish Capital Markets Act, which typically governs major shareholding disclosures. The content focuses on the notification of a significant shareholding level crossing a threshold, which is characteristic of a Major Shareholding Notification. There is no financial data, earnings information, or management discussion present. The document is not an announcement of a report publication but a direct announcement of shareholding information. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-05-08 Danish
6-K - GENMAB A/S (0001434265) (Filer)
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 6-K filing by a foreign private issuer (Genmab A/S), which serves as a regulatory submission under the Exchange Act. It contains an exhibit index pointing to an interim report but does not itself present substantive financial statements or analysis. Under the classification rules, this type of SEC form is a general regulatory filing and falls into the RNS (Regulatory Filings) category.
2026-05-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.